First reported at 5,523 shares this quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2024-12-31 | 331 |
| 2025-03-31 | 80 |
| 2025-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2025 | Reduced | 0 | -110 (-100.0%) | 0 | $0 | 2025-08-08 | |
| Q1 2025 | Reduced | 110 | -5,413 (-98.0%) | < 0.01% | $80 | 2025-05-02 | |
| Q4 2024 | New | 5,523 | +5,523 (0.0%) | < 0.01% | $331 | 2025-02-06 |
Who else reported the position
1 manager reported CERO THERAPEUTICS HLDGS INC for Q4 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| SBI Securities Co Ltd This report | New | 5,523 | +5,523 | < 0.01% | $331 | 1 qtr |
Filing details and methodology As reported
- Report period
- December 31, 2024
- Filed
- February 06, 2025
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 5,523
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.